Please ensure Javascript is enabled for purposes of website accessibility

Why DBV Technologies Stock Is Plunging Today

By George Budwell - Jan 30, 2020 at 12:39PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A sizable capital raise sent shareholders running for the exits this morning.

What happened

DBV Technologies S.A. (DBVT -5.93%), a clinical-stage food allergy company, is having a tough go of it today. The company's shares are down by a hefty 13.3% on over six times the average daily volume, as of 11:39 a.m. EST. 

What's causing investors to run for the exits this morning? Before the opening bell, DBV Technologies announced a sizable global offering of its stock. The offering will reportedly yield gross proceeds of $153.7 million for the company upon closing. DBV Technologies said that the offering should close on Feb. 4, 2020.  

A man with a look of shock on his face standing in front of a graph displaying a downward trend.

Image Source: Getty Images.

So what

Investors probably shouldn't be too shocked over this substantial capital raise. DBV Technologies, after all, is busy gearing up for the potential launch of its peanut allergy medication dubbed Viaskin Peanut. Unfortunately, the company didn't have nearly enough cash to fund a commercial launch, resulting in today's noteworthy capital raise. Per the press release, DBV Technologies said the funds from this stock sale should extend its cash runway until the first quarter of 2021. That's not exactly an extensive cash runway, however, meaning another capital raise could happen before year's end. 

Now what

Is this double-digit drop in DBV Technologies' share price a buying opportunity? If Viaskin Peanut lives up to some of Wall Street's more optimistic sales projections that presently stand at over $2.2 billion, then the answer is a resounding yes. The company's market cap, after all, is currently less than half of this peak sales forecast. That said, the company will likely have to tap the public markets yet again well before this product starts to become a viable cash cow. As such, this small-cap biopharma stock is arguably best viewed as a intriguing watch list candidate for the time being. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

DBV Technologies S.A. Stock Quote
DBV Technologies S.A.
$2.38 (-5.93%) $0.15

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.